美股市场个股详情
ALNY 阿里拉姆制药
- 281.490
- -3.200-1.12%
收盘价 10/30 16:00 (美东)
- 282.000
- +0.510+0.18%
盘后 17:58 (美东)
361.38亿总市值-502660市盈率TTM
287.870最高价281.390最低价97.64万股成交量284.100今开284.690昨收2.77亿成交额0.76%换手率亏损市盈率(静)1.28亿总股本304.39052周最高-11728.75市净率359.86亿流通值141.97552周最低--股息TTM1.28亿流通股304.390历史最高--股息率TTM2.28%振幅3.650历史最低283.885平均价1股每手
关于阿里拉姆制药公司
Alnylam Pharmaceuticals是RNA干扰(RNAi)治疗研究的领导者。RNAi是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。Alnylam有5种药物上市:Onpattro和Amvuttra治疗hATTR淀粉样变，Givlaari治疗急性肝卟啉，Oxlumo治疗原发性高草酸尿1型，Leqvio治疗高胆固醇血症。它也有几个不同治疗领域的临床项目:遗传药物;cardio-metabolic疾病;肝脏感染性疾病和中枢神经系统/眼部疾病。来自研究合作伙伴的预付费用提高了Alnylam的现金水平，该公司有望从合作伙伴关系下的药物商业化中看到更多的里程碑和版税。
公司介绍
公司代码ALNY
公司名称阿里拉姆制药
上市日期2004/05/27
发行价格6.00
成立日期2002
CEODr. Yvonne L Greenstreet, MB.Ch.B.
所属市场纳斯达克
员工数量2100
年结日12-31
公司地址675 West Kendall Street,Henri A. Termeer Square
城市Cambridge
省份马萨诸塞州
国家美国
邮编02142
电话1-617-551-8200
董事高管
- 姓名
- 职务
- 年薪
- Dr. Yvonne L Greenstreet, MB.Ch.B.
- Director and Chief Executive Officer
- 889.57万
- Kevin Joseph Fitzgerald, PhD
- Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development
- --
- Dr. Akshay K. Vaishnaw, M.D.,PhD
- Chief Innovation Officer
- 331.72万
- Dr. Pushkal P. Garg, M.D.
- Chief Medical Officer and Executive Vice President, Development and Medical Affairs
- 323.11万
- Tolga Tanguler
- Chief Commercial Officer
- 286.97万
- Jeffrey V. Poulton
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 322.44万
- Amy W. Schulman
- Chairman of the Board
- 53.14万
- Michael W. Bonney
- Director
- 46.72万
- Colleen F. Reitan
- Independent Director
- 48.92万
- Dr. Phillip A. Sharp,PhD
- Independent Director
- 50.22万
- Dr. Olivier Raymond Brandicourt, M.D.
- Independent Director
- 48.10万
- Dr. Elliott Sigal, M.D.,PhD
- Independent Director
- 47.01万
- David E.I. Pyott, M.B.A.,M.D.
- Independent Director
- 47.72万
- Dr. Margaret A. Hamburg, M.D.
- Independent Director
- 47.14万
- Dr. Dennis A. Ausiello, M.D.
- Independent Director
- 47.72万
- Dr. Carolyn R. Bertozzi, PhD
- Independent Director
- 66.89万
- Peter N. Kellogg
- Independent Director
- 65.87万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据